‘Achelios’ ACHETOGEL™ delivery technology offers an exclusive IP position. Achelios holds drug delivery system patents that serve as the backbone for its value creation proposition. The drug delivery system patents relate to aqueous pharmaceutical compositions for the transdermal administration of water-insoluble drugs to a patient.
Achelios holds a broad composition patent applicable to drugs in development, specifically ketoprofen, diclofenac, naproxen, and ibuprofen. The composition of the formulation patent relates to a non-irritating topical analgesic for the treatment of various pains, such as nociceptive pain, inflammatory pain, pathological pain, and migraine pain. In addition, the company has received a method-of-use patent for topical ketoprofen, as well as diclofenac, naproxen, and ibuprofen, in the indication of acute and chronic migraine, temporomandibular joint pain and neuropathic pain.
|US 8,822,537 B2||Ketoprofen formulation|
|6,083,996||NSAI drug delivery|
|WO 2017/106714||Treatment of neuropathy|
|20190216720 A1||Treatment of pain & Migraine|
|2013/0109674||Treatment of trigeminal neuralgias and facial pain|
|2019/0105290||Treatment of cephalgias|
|11,026,882||Treatment of migraine pain|
|US20180271813A1||Sprayable analgeic formulation|